- Akeso’s half-year revenue stood at 1.41 billion yuan, falling short of the estimated 1.48 billion yuan.
- The gross profit achieved was 1.12 billion yuan, below the estimated 1.28 billion yuan.
- Research and Development expenses were higher than expected, totaling 731.2 million yuan compared to the estimate of 633.4 million yuan.
- Selling and marketing expenses were 669.9 million yuan, surpassing the forecasted 628.8 million yuan.
- Administrative expenses exceeded projections, reaching 134.0 million yuan versus the anticipated 119.8 million yuan.
- The company enjoys a positive sentiment from analysts with 29 buy ratings, 1 hold rating, and no sell ratings.
“`
Akeso Biopharma Inc on Smartkarma
According to a recent report by Xinyao (Criss) Wang on Smartkarma, Akeso Biopharma Inc is under the spotlight for its high valuation, primarily driven by the success of HARMONi-3 and HARMONi-7 over HARMONi-2. However, there are concerns regarding the final OS data, with doubts raised about the MRCT and the lower-than-expected safety margin. The report suggests that Akeso’s valuation is not undervalued, and there are lingering uncertainties in the market regarding the company’s future performance.
Xinyao (Criss) Wang also notes that the exchange rate of HKD has hit its upper limit, hinting at potential capital inflows post Labor Day that could boost Hong Kong stock prices. Meanwhile, the report indicates that Mindray, another player in the healthcare sector, is facing challenges with a potential turning point projected for 2026. Investors are looking for a new growth narrative from Mindray, with a fair valuation set at 20-25x TTM P/E. This analysis provides valuable insights for investors tracking the developments at Akeso Biopharma Inc and the broader market trends in the healthcare sector.
A look at Akeso Biopharma Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Akeso Biopharma Inc seems to have a promising long-term outlook. With high scores in both Growth and Momentum, the company is positioned well for future expansion and market performance. The focus on developing innovative treatments and therapies for diseases aligns with the company’s strong growth potential, indicating a positive trajectory ahead.
Although Akeso Biopharma Inc scores lower on Value and Dividend factors, the resilience score of 3 suggests a moderate ability to withstand market challenges. The combination of solid growth and momentum scores, along with a strong focus on research and development, indicates that Akeso Biopharma Inc could be a leading player in the biopharmaceutical industry in the coming years, offering potential opportunities for investors seeking growth and innovation in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
